Cerebrospinal fluid homovanillic acid in the datatop study on parkinson's disease

Archives of Neurology

Volumn 52, Issue 3, 1995, Pages 237-245

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIOXIDANT; HOMOVANILLIC ACID; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SELEGILINE; TOCOPHEROL;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PLACEBOS; SELEGILINE; VITAMIN E;

EID: 0028954732     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1995.00540270025015     Document Type: Article

References (31)

1. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London, England: Butterworth Scientific; 1982:41-58.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci. 1973; 20:415-455.
3. Tyce GM, Messick JM, Yaksh TL, Byer DE, Danielson DR, Rorie DK. Amine sulfate formation in the central nervous system. Fed Proc. 1986;45:2247-2253.
4. LeWitt PA, Galloway MP, Matson W, et al, Parkinson Study Group. Markers of dopamine metabolism in Parkinson's disease. Neurology. 1992;42:2111-2117.
5. LeWitt PA, Galloway MP. Neurochemical markers of Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's Disease. New York, NY: Marcel Dekker Inc; 1990:63-93.
6. Chase TN. Neurochemical alterations in Parkinson's disease. In: Wood JH, ed. Neurobiology of Cerebrospinal Fluid. New York, NY: Plenum Press; 1980:207-218.
7. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46:1052-1060.
8. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
9. Parkinson Study Group. The effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993:328: 176-183.
10. LeWitt PA, Galloway M, Oakes D, Watts A, Matson W, Parkinson Study Group. Homovanillic acid, other monoamine neurotransmitter metabolites, and xanthine in parkinsonian CSF. Neurology. 1991;41 (suppl 1):379.
11. LeWitt PA, Bannon M, Galloway M, et al, Parkinson Study Group. Monoaminergic metabolism, substance P, met-enkephalin, and biopterin metabolism in Parkinson's disease. Neurology. 1993;43:A408. Abstract.
12. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Boston, Mass: Blackwell Scientific Publications Inc; 1987.
13. Fahn S, Elton RL, Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987;2:153-163, 293-304.
14. Cleveland WS. Robust locally weighted regression and smoothing scatter-plots. JAm Stat Assoc. 1979;74:829-836.
15. LeWitt PA, Galloway M, Matson W, Milbury P, McDermott M, Oakes D, Parkinson Study Group. Markers of endogenous dopamine synthesis in Parkinson's disease. Neurology. 1992;42(suppl 3):420. Abstract.
16. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand. 1984;69:201-219.
17. Almay BGL, Haggendal J, von Knorring L, Oreland L. 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. Biol Psychiatry. 1987;22:403-412.
18. Schwab RS, England AC Jr. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
20. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology. 1978;57:33-38.
21. Oreland L. Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand. 1991;84:60-65.
22. Arnett CD, Fowler JS, MacGregor RR, et al. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl. J Neurochem. 1987;49:522-527.
23. Hildebrand J, Bourgeois F, Buyse M, Przedborski S, Goldman S. Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid. Acta Neurol Scand. 1990;81:427-430.
24. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol. 1993;33:350-356.
25. Heinonen EH, Savijarvi M, Kotila M, Hajba A, Scheinin M. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 1993;5:193-202.
26. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol. 1986;45:119-125.
27. Westlund KN, Denney RM, Korchersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science. 1985;230: 181-183.
28. Konradi C, Kornhuber J, Froelich L, et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience. 1989;33:383-400.
29. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology. 1990;40 (suppl 3):32-37.
30. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology. 1992;42:2241-2250.
31. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992;32:804-812.